ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
71.14
+0.39 (0.55%)
Apr 29, 2025, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ANI Pharmaceuticals stock have an average target of 80.13, with a low estimate of 65 and a high estimate of 94. The average target predicts an increase of 12.64% from the current stock price of 71.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $62 → $65 | Hold | Maintains | $62 → $65 | -8.63% | Apr 21, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $86 | Strong Buy | Reiterates | $86 | +20.89% | Apr 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $94 | Strong Buy | Reiterates | $94 | +32.13% | Mar 17, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +12.45% | Mar 14, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $85 | Buy | Initiates | $85 | +19.48% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
784.46M
from 614.38M
Increased by 27.68%
Revenue Next Year
845.16M
from 784.46M
Increased by 7.74%
EPS This Year
6.45
from -1.04
EPS Next Year
7.11
from 6.45
Increased by 10.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 811.9M | 910.9M | 995.5M | ||
| Avg | 784.5M | 845.2M | 900.6M | ||
| Low | 747.0M | 778.6M | 803.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.1% | 16.1% | 17.8% | ||
| Avg | 27.7% | 7.7% | 6.6% | ||
| Low | 21.6% | -0.7% | -5.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.79 | 8.48 | 10.43 | ||
| Avg | 6.45 | 7.11 | 8.23 | ||
| Low | 6.09 | 6.30 | 6.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 31.6% | 46.6% | ||
| Avg | - | 10.3% | 15.7% | ||
| Low | - | -2.3% | -6.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.